Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 2.77 EUR -3.82% Market Closed
Market Cap: 29.8m EUR
Have any thoughts about
Biosynex SA?
Write Note

Operating Margin
Biosynex SA

-35.6%
Current
3%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-35.6%
=
Operating Profit
-37m
/
Revenue
104m

Operating Margin Across Competitors

Country FR
Market Cap 28.9m EUR
Operating Margin
-36%
Country US
Market Cap 204.9B USD
Operating Margin
17%
Country US
Market Cap 195.2B USD
Operating Margin
26%
Country US
Market Cap 146.7B USD
Operating Margin
22%
Country US
Market Cap 132.6B USD
Operating Margin
18%
Country IE
Market Cap 110.6B USD
Operating Margin
19%
Country US
Market Cap 64.7B USD
Operating Margin
14%
Country DE
Market Cap 55.6B EUR
Operating Margin
12%
Country CN
Market Cap 319.2B CNY
Operating Margin
37%
Country US
Market Cap 41.6B USD
Operating Margin
28%
Country US
Market Cap 37.7B USD
Operating Margin
13%
No Stocks Found

Biosynex SA
Glance View

Market Cap
28.9m EUR
Industry
Health Care

Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

ALBIO Intrinsic Value
7.73 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-35.6%
=
Operating Profit
-37m
/
Revenue
104m
What is the Operating Margin of Biosynex SA?

Based on Biosynex SA's most recent financial statements, the company has Operating Margin of -35.6%.